To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Inclusion Criteria: * Histologically or cytologically confirmed malignant digestive system tumors; * Patients with advanced recurrent, unresectable and / or metastatic digestive system tumors who have failed standard or conventional treatment:( definition of treatment failure: intolerable toxic and side effects, disease progression during treatment recurrence after treatment); * Eastern Cooperative Oncology Group performance status score of 0 or 1; * Life expectancy \> 12 weeks; * BMI≥18.0; * Has adequate Hematologic, renal, and hepatic function; * Patients should participate in the study voluntarily and sign informed consent. Exclusion Criteria: * Any patient who is known to have central nervous system (CNS) metastasis with clinical symptoms; * Other kinds of malignancies; * Gastrointestinal abnormalitiest; * Cardiovascular and cerebrovascular diseases; * Previous treatment with small molecule vascular targeting inhibitor； * Prior anti-tumor therapies with chemotherapy, radiotherapy, hormonotherapy, biotherapy, immunotherapy, operation within 4 weeks before enrollment; * Involved in other clinical trials within 4 weeks before enrollment; * Major surgical procedure, open biopsy, or significant traumatic injury 4 weeks before enrollment; * Uncontrolled massive ascites,pleural/pericardial effusion; * Uncontrolled ongoing or active bacterial, viral or fungal infectious; Fever of unknown cause (\> 38.5 ℃) occurred within 2 weeks before enrollment; * Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection ; * Pregnant or lactating women or those who do not take contraceptives, including men; * Any other metabolic dysfunction, abnormal physical examination findings, or clinical laboratory findings; * Inability to comply with protocol required procedures.